P0X Stock Overview
A clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Pharnext S.C.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0001 |
| 52 Week High | €50.00 |
| 52 Week Low | €0.0001 |
| Beta | -313.29 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -100.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| P0X | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.1% | -0.1% |
| 1Y | -100.0% | -9.7% | 7.4% |
Return vs Industry: P0X underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: P0X underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| P0X volatility | |
|---|---|
| P0X Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: P0X's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine P0X's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 19 | Hugo Brugiere | pharnext.com |
Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases. The company was incorporated in 2007 and is headquartered in Suresnes, France.
Pharnext S.C.A. Fundamentals Summary
| P0X fundamental statistics | |
|---|---|
| Market cap | €34.00 |
| Earnings (TTM) | -€27.52m |
| Revenue (TTM) | €171.94k |
0.0x
P/S Ratio0.0x
P/E RatioIs P0X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P0X income statement (TTM) | |
|---|---|
| Revenue | €171.94k |
| Cost of Revenue | €19.35m |
| Gross Profit | -€19.18m |
| Other Expenses | €8.34m |
| Earnings | -€27.52m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -158.25 |
| Gross Margin | -11,153.39% |
| Net Profit Margin | -16,004.27% |
| Debt/Equity Ratio | -81.6% |
How did P0X perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/11/23 02:17 |
| End of Day Share Price | 2024/08/26 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharnext S.C.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Soo Romanoff | Edison Investment Research |
| Damien Choplain | Kepler Cheuvreux |